Erdafitinib not checked

Johnson & Johnson (Janssen) · JNJ-42756493 · G-024

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 1/2 trial completes
Trials
6 active
17 in total · 8 in the EU
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
How it’s given
“Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.”In the company’s words, NCT03390504 on ClinicalTrials.gov
Tested for
Urothelial Cancer (2 trials), Urothelial Carcinoma, Non-Muscle Invasive Bladder Neoplasms
Main trialPhase 3
“The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\[L\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).”In the company’s words, NCT03390504 on ClinicalTrials.gov
Other names
JNJ-42756493 · G-024

Other drugs for Urothelial Cancer

All 85 drugs for Urothelial Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials17

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 15 Apr 2024 A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Phase 2Active, not recruiting 15 Sep 2022 An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Phase 1/2Active, not recruiting 30 Sep 2022 A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Phase 1/2Active, not recruiting 30 Mar 2028 Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Phase 2Completed 12 Oct 2021 A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
Phase 2Completed 4 Dec 2023 A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Phase 2Completed 12 Jul 2024 A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Phase 1/2Completed 13 May 2019 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma
Phase 1Completed Aug 2015 A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets
Phase 1Completed 5 Jul 2017 A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
Phase 1Completed 1 Sep 2017 A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants
Phase 1Terminated 22 Dec 2020 A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib
Phase 1Completed 14 Jun 2022 A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants
Phase 1Completed 4 Jul 2022 A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
Phase 1Completed 11 Mar 2025 A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
Phase 2Authorised not given A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
Phase 2Authorised not given A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monotherapy and erdafitinib (ERDA) and cetrelimab (CET) combination as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations (SOGUG-NEOWIN)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Erdafitinib

Following is part of Solo: you see every change to Erdafitinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in